1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------
FORM 10-Q
QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarter ended Commission File
June 30, 2000 No. 1-9767
----------------------
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
Delaware 94-2579751
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
9162 Eton Avenue, Chatsworth CA. 91311
(Address of principal executive offices) (Zip Code)
Telephone Number: 818-709-1244
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [X] No [ ]
The number of shares of Common Stock of the registrant outstanding as
of July 31, 2000 was 9,726,087.
2
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
INDEX TO FORM 10-Q
Three and Six Months Ended June 30, 2000
PAGE
PART I - FINANCIAL INFORMATION
ITEM 1 - Consolidated Financial Statements
Consolidated Balance Sheets........................................................2
Consolidated Statements of Operations..............................................3
Consolidated Statements of Cash Flows..............................................7
Consolidated Statements of Comprehensive Income....................................9
Notes to Consolidated Financial Statements........................................10
ITEM 2 - Management's Discussion and Analysis of
Financial Condition and Results of Operations..........................15
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk...............22
PART II - OTHER INFORMATION
ITEM 1 - Legal Proceedings........................................................22
ITEM 2 - Sales of Unregistered Securities.........................................22
ITEM 4 - Submission of Matters to a Vote of Security Holders......................22
ITEM 6 - Exhibits and Reports on Form 8-K
(a) Exhibits.................................................................22
(b) Reports on Form 8-K......................................................23
SIGNATURE.....................................................................................23
1
3
PART I
FINANCIAL INFORMATION
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
CONSOLIDATED BALANCE SHEETS
ASSETS
At December 31, At June 30,
1999 2000
--------------- ------------
(unaudited)
Current assets:
Cash and cash equivalents $ 2,034,593 $ 3,024,812
Accounts receivable, net of allowance for doubtful
accounts of $516,047 in 1999 and $361,180 in 2000 6,444,865 5,067,773
Inventories 3,360,468 3,377,522
Prepaid expenses and other current assets 355,935 260,641
Deferred tax asset 1,005,908 1,248,579
--------------- ------------
Total current assets 13,201,769 12,979,327
Property and equipment, at cost, net of accumulated depreciation
of $5,870,670 in 1999 and $5,154,851 in 2000 1,553,942 1,236,724
Purchased intangibles, net of accumulated amortization
of $124,813 in 1999 and $142,159 in 2000 258,295 240,950
Software development costs, net of accumulated amortization of
$1,782,410 in 1999 and $1,297,591 in 2000 474,616 266,885
Deferred tax asset 10,351,336 9,412,734
Other assets 821,167 1,729,129
--------------- ------------
Total assets $ 26,661,125 $ 25,865,749
=============== ============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Short-term borrowings $ 655,036 $ 380,960
Current portion of long-term debt 1,200,000 1,100,000
Accounts payable 2,466,389 2,508,690
Accrued expenses 2,647,975 2,214,716
Deferred income - service contracts and other 1,140,737 704,870
--------------- ------------
Total current liabilities 8,110,137 6,909,236
Subordinated note payable 7,000,000 7,000,000
Deferred income - service contracts and other 829,281 441,481
Notes payable, long-term portion 500,000 --
--------------- ------------
Total liabilities 16,439,418 14,350,717
Commitments and contingencies
Shareholders' equity:
Preferred stock, $.01 par value; Authorized: 3,000,000 shares;
Callable Series B shares issued and outstanding:
1999 - 198,000 ($594,000 liquidation preference)
2000 - 204,000 ($612,000 liquidation preference) 1,980 2,040
Common stock, $.01 par value; Authorized: 15,600,000 shares
Shares issued and outstanding: 1999 - 9,347,325 and 2000 - 9,707,514 93,473 97,074
Additional paid-in capital 39,529,777 40,163,509
Unearned compensation (153,108) (255,867)
Foreign currency translation adjustment 67,207 --
Accumulated deficit (29,317,622) (28,491,724)
--------------- ------------
Total shareholders' equity 10,221,707 11,515,032
--------------- ------------
Total liabilities and shareholders' equity $ 26,661,125 $ 25,865,749
=============== ============
- ---------------
The accompanying notes are an integral part of these consolidated financial
statements.
2
4
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
For the three months ended June 30,
-----------------------------------
1999 2000
----------- ------------
Sales of IVD systems $ 1,716,679 $ 2,005,428
Sales of IVD supplies and services 3,240,054 3,635,482
Sales of small instruments and supplies 1,123,815 1,786,181
Royalties and licensing revenues 37,299 49,390
----------- ------------
Net revenues 6,117,847 7,476,481
----------- ------------
Cost of goods - IVD systems 1,153,834 1,320,961
Cost of goods - IVD supplies and services 1,401,599 1,396,260
Cost of goods - small instruments and supplies 618,363 920,590
----------- ------------
Cost of goods sold 3,173,796 3,637,811
----------- ------------
Gross margin 2,944,051 3,838,670
Marketing and selling 848,481 1,011,083
General and administrative 846,392 948,885
Research and development, net 279,626 596,932
Amortization of intangibles 70,283 33,724
Unusual charges 426,542 --
----------- ------------
Total operating expenses 2,471,324 2,590,624
Operating income 472,727 1,248,046
Other income (expense):
Interest income 9,639 50,061
Interest expense (261,751) (242,876)
Other income 871 11,178
----------- ------------
Income from continuing operations before provision 221,486 1,066,409
for income taxes
Provision for income taxes 105,328 392,277
----------- ------------
Income from continuing operations 116,158 674,132
Loss from discontinued operations:
Loss from operations of discontinued segment prior to
March 31, 2000, net of tax benefit of $112,580 (235,902) --
Loss on disposal of discontinued segment,
including tax provision of $29,374 -- (199,159)
----------- ------------
Loss from discontinued operations (235,902) (199,159)
----------- ------------
Net income (loss) $ (119,744) $ 474,973
=========== ============
3
5
Income (loss) per share - basic:
Income (loss) from continuing operations $ 0.02 $ 0.07
Loss from discontinued operations (0.04) (0.02)
----------- ------------
Income (loss) per share attributable to common shareholders - basic $ (0.02) $ 0.05
=========== ============
Income (loss) per share - diluted:
Income (loss) from continuing operations $ 0.01 $ 0.07
Loss from discontinued operations (0.02) (0.02)
----------- ------------
Income (loss) per share attributable to common shareholders - diluted $ (0.01) $ 0.05
=========== ============
Weighted average number of common shares outstanding - basic 6,490,422 9,649,658
Weighted average number of common shares outstanding - diluted 8,493,901 10,325,890
- ---------------
The accompanying notes are an integral part of these consolidated financial
statements.
4
6
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
For the six months ended June 30,
---------------------------------
1999 2000
------------ ------------
Sales of IVD systems $ 2,756,465 $ 3,519,153
Sales of IVD supplies and services 6,489,840 7,155,051
Sales of small instruments and supplies 2,258,085 3,129,010
Royalties and licensing revenues 102,247 426,405
------------ ------------
Net revenues 11,606,637 14,229,619
------------ ------------
Cost of goods - IVD systems 1,826,307 2,325,101
Cost of goods - IVD supplies and services 2,813,241 2,909,567
Cost of goods - small instruments and supplies 1,225,759 1,619,349
------------ ------------
Cost of goods sold 5,865,307 6,854,017
------------ ------------
Gross margin 5,741,330 7,375,602
Marketing and selling 1,726,393 1,842,746
General and administrative 1,605,186 1,970,426
Research and development, net 584,275 1,020,651
Amortization of intangibles 140,345 70,673
Unusual charges 2,043,273 --
------------ ------------
Total operating expenses 6,099,472 4,904,496
Operating income (loss) (358,142) 2,471,106
Other income (expense):
Interest income 16,649 83,318
Interest expense (544,076) (484,627)
Other income 3,225 11,857
------------ ------------
Income (loss) from continuing operations before provision (882,344) 2,081,654
(benefit) for income taxes
Provision (benefit) for income taxes (68,777) 770,212
------------ ------------
Income (loss) from continuing operations (813,567) 1,311,442
Loss from discontinued operations:
Loss from operations of discontinued segment prior to (625,246) (286,385)
March 31, 2000, net of tax benefit of $231,269 in 1999
and $61,015 in 2000
Loss on disposal of discontinued segment, including tax
provision of $29,374 -- (199,159)
------------ ------------
Loss from discontinued operations (625,246) (485,544)
------------ ------------
Net income (loss) $ (1,438,813) $ 825,898
============ ============
5
7
Income (loss) per share - basic:
Income (loss) from continuing operations $ (0.12) $ 0.14
Loss from discontinued operations (0.10) (0.05)
-------------- --------------
Income (loss) per share attributable to common shareholders - basic $ (0.22) $ 0.09
============== ==============
Income (loss) per share - diluted:
Income (loss) from continuing operations $ (0.12) $ 0.13
Loss from discontinued operations (0.10) (0.05)
-------------- --------------
Income (loss) per share attributable to common shareholders - diluted $ (0.22) $ 0.08
============== ==============
Weighted average number of common shares outstanding - basic 6,461,807 9,513,836
Weighted average number of common shares outstanding - diluted 6,461,807 10,280,304
- -----------------
The accompanying notes are an integral part of these consolidated financial
statements.
6
8
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
For the six months ended June 30,
---------------------------------
1999 2000
----------- -----------
Cash flow from operating activities:
Net income (loss) $(1,438,813) $ 825,898
Adjustments to reconcile net income (loss) to net cash provided by
operations:
Loss from discontinued operations -- 485,544
Deferred tax benefit (322,273) 700,884
Depreciation and amortization 1,204,256 376,627
Common stock and stock option compensation amortization 114,198 113,384
Gain on disposal of equipment (87,158) (1,677)
Litigation settlement payable in equity securities 1,520,371 --
Changes in assets and liabilities:
Accounts receivable - trade and other 108,370 319,647
Service contracts, net 330,973 (305,605)
Inventories 445,744 (300,063)
Prepaid expenses and other current assets (52,172) 22,268
Other assets (24,124) (68,581)
Accounts payable (532,210) 405,724
Accrued expenses 232,034 424,369
----------- -----------
Net cash provided by continuing operations 1,499,196 2,998,419
Net cash used by discontinued operations -- (858,988)
----------- -----------
Net cash provided by operating activities 1,499,196 2,139,431
----------- -----------
Cash flow from investing activities:
Acquisition of property and equipment (93,835) (151,544)
Software development costs (202,307) (31,935)
Sale of equipment 125,000 --
Investing activities of discontinued operations -- (136,694)
----------- -----------
Net cash used by investing activities (171,142) (320,173)
----------- -----------
Cash flow from financing activities:
Borrowings under credit facility 6,554,651 7,110,000
Repayments of credit facility (6,192,596) (7,384,076)
Repayment of notes payable (906,077) (604,713)
Issuance of common stock and warrants for cash 40,581 49,750
----------- -----------
Net cash used by financing activities (503,441) (829,039)
----------- -----------
Effect of foreign currency fluctuation on cash and cash equivalents 17,264 --
----------- -----------
Net increase in cash and cash equivalents 841,877 990,219
Cash and cash equivalents at beginning of period 389,495 2,034,593
----------- -----------
Cash and cash equivalents at end of period $ 1,231,372 $ 3,024,812
=========== ===========
7
9
Supplemental schedule of non-cash investing and financing activities:
Issuance of common stock in exchange for services 54,232 80,500
Addition to capital lease obligation -- 33,840
Issuance of common stock in satisfaction of liabilities 7,650 --
Supplemental disclosure of cash flow information:
Cash paid for interest 506,775 432,497
Cash paid for income taxes 23,082 14,596
- ----------------------
The accompanying notes are an integral part of these consolidated financial
statements.
8
10
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(unaudited)
For the three months ended June 30,
-----------------------------------
1999 2000
--------- --------
Net income (loss) $(119,744) $474,973
Other comprehensive income,
foreign currency translation adjustment 6,259 --
--------- --------
Comprehensive income (loss) $(113,485) $474,973
========= ========
For the six months ended June 30,
---------------------------------
1999 2000
----------- --------
Net income (loss) $(1,438,813) $825,898
Other comprehensive income,
foreign currency translation adjustment 8,197 --
----------- --------
Comprehensive income (loss) $(1,430,616) $825,898
=========== ========
- -------------
The accompanying notes are an integral part of these consolidated financial
statements.
9
11
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. FORMATION AND BUSINESS OF THE COMPANY.
International Remote Imaging Systems, Inc. was incorporated in California
in 1979 and reincorporated during 1987 in Delaware. International Remote Imaging
Systems, Inc. and its subsidiaries (collectively "IRIS" or the "Company")
designs, develops, manufactures and markets in vitro diagnostic ("IVD")
equipment, including IVD imaging systems based on patented and proprietary
automated intelligent microscopy ("AIM") technology, and special purpose
centrifuges and other small instruments for automating microscopic procedures
performed in clinical laboratories. The Company also provides ongoing service
and supplies to support the equipment sold.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES.
Basis of Presentation of Unaudited Interim Financial Statements:
In the opinion of management, the accompanying unaudited consolidated
financial statements contain all normal recurring adjustments necessary to
present fairly the financial position of the Company as of June 30, 2000 and
1999 and the results of its operations for the three and six month periods then
ended. These financial statements should be read in conjunction with the
financial statements and notes included in the Company's latest annual report on
Form 10-K. Interim results are not necessarily indicative of results for a full
year.
Use of Estimates:
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amount of revenues and expenses during the reporting
periods. The significant estimates in the preparation of the consolidated
financial statements relate to the assessment of the carrying value of accounts
receivables, inventories, purchased intangibles, estimated provisions for
warranty costs and deferred tax assets. Actual results could differ from those
estimates.
Principles of Consolidation:
The consolidated financial statements include the accounts of International
Remote Imaging Systems, Inc. and its wholly-owned subsidiaries. All significant
intercompany accounts and transactions have been eliminated in the consolidated
financial statements.
Reclassifications:
Certain reclassifications have been made to the 1999 financial statements
to conform to the 2000 presentation.
3. COMPREHENSIVE INCOME.
In prior periods, the Company's components of comprehensive income were net
income and foreign currency translation adjustments. After the disposal of PSI's
international operations, the Company has no other comprehensive income items
and, accordingly, comprehensive income is net income.
4. INVENTORIES.
Inventories are carried at the lower of cost or market on a first-in
first-out basis and consist of the following:
At December 31, 1999 At June 30, 2000
-------------------- ----------------
Finished goods $ 842,952 $ 794,433
Work-in-process 350,424 477,437
Raw materials, parts and sub-assemblies 2,167,092 $2,105,652
---------- ----------
$3,360,468 $3,377,522
========== ==========
10
12
5. SHORT-TERM BORROWINGS AND NOTES PAYABLE.
At June 30, 2000, the outstanding amount under the credit facility with
Foothill Capital Corporation consists of $1.1 million outstanding under a $3.6
million term loan and $381,000 outstanding under a $4.0 million revolving line
of credit. Borrowings under the line of credit are limited to a percentage of
eligible accounts receivable. The Company had approximately $2.2 million
available under the line of credit at June 30, 2000. The term loan bears
interest at the lender's prime rate (9.5% on June 30, 2000) plus 3.0% and is
payable in monthly installments of $100,000. The revolving credit line bears
interest at the lender's prime rate plus 1.0%. The credit facility is subject to
minimum interest charges, prepayment penalties and customary fees, is
collateralized by a first priority lien on all assets of the Company and matures
in 2001. It also contains financial covenants based primarily on tangible net
worth and cash flows and imposes restrictions on acquisitions, capital
expenditures and cash dividends.
6. CAPITAL STOCK.
Stock Issuances:
During the six months ended June 30, 2000, the Company (i) issued 20,831
shares of common stock in exchange for $13,500 in cash and services under the
Employee Stock Purchase Plan, (ii) issued options to purchase 315,050 shares of
common stock under the Company's stock option plans and (iii) cancelled options
to purchase 105,916 shares of common stock. Options for 20,802 shares of common
stock were exercised during the period. At June 30, 2000, options to purchase
2,205,983 shares of common stock were issued and outstanding under the Company's
stock options plans. The outstanding options expire by the end of 2010. The
exercise price for these options ranges from $0.69 to $4.38 per share. At June
30, 2000, there were 249,383 shares of common stock available for the granting
of future options under the Company's stock option plans. Included in the
options outstanding at June 30, 2000 were options to purchase 150,000 shares
which had been issued subject to the authorization of additional shares under an
existing stock option plan. Such authorization was granted at the Company's
annual meeting in May.
During the six months ended June 30, 2000, the Company issued 309,556
shares of common stock, 6,000 shares of preferred stock and warrants to purchase
an additional 18,000 shares of common stock in exchange for 57,000 shares of the
common stock of Poly U/A Systems that had not been acquired through the tender
offer which took place in 1999.
Warrants
During the six months ended June 30, 2000, warrants were exercised to
purchase 9,000 shares of common stock for $9,000. Also, warrants to purchase an
additional 100,000 shares of common stock were issued in exchange for future
services. During the period, warrants to purchase 75,000 shares of common stock
expired unexercised and the expiration date of 298,633 other warrants was
extended by one year.
As of June 30, 2000, the following warrants to purchase shares of common
stock were outstanding and exercisable:
Number of Shares Per Share Price Expiration Date
---------------- --------------- ---------------
25,000 4.0625 July 1, 2000
123,000 7.80 September 28, 2000
298,633 4.00 April 3, 2001
875,000 3.56 July 31, 2001
84,270 3.56 December 31, 2001
100,000 1.50 February 10, 2002
10,000 4.31 May 15, 2002
306,000 2.00 August 6, 2002
297,000 1.00 August 6, 2002
11
13
7. INCOME TAXES.
The income tax provision from continuing operations for the six-month
period ended June 30, 2000 was $770,212 as compared to an income tax benefit of
$68,777 for the comparable period last year. The income tax provision for the
three-month period ended June 30, 2000 was $392,277, as compared to $105,328 in
the prior year. The income tax provision and benefit differs from the federal
statutory rate due primarily to state income taxes, unutilized foreign losses,
permanent differences between income reported for financial statement and income
tax purposes and changes in the tax valuation allowance relating to the
company's net operating loss carryforwards.
Realization of deferred tax assets associated with NOL and credit
carryforwards is dependent upon generating sufficient taxable income prior to
their expiration. Management believes that there is a risk that certain of these
NOL and credit carryforwards may expire unused and accordingly, has established
a valuation reserve against them. Although realization is not assured for the
remaining deferred tax assets, management believes it is more likely than not
that they will be realized through future taxable income or alternative tax
strategies. However, the net deferred tax assets could be reduced in the near
term if management's estimates of taxable income during the carryforward period
are significantly reduced or alternative tax strategies are not available. The
Company will continue to review its valuation allowances and make adjustments,
if necessary. Also, although a valuation allowance has been provided against a
portion of its NOL's, should the Company undergo an ownership change as defined
in Section 382 of the Internal Revenue Code, the Company's tax NOL generated
prior to the ownership change would be subject to an annual limitation. If this
occurred a further adjustment of the valuation allowance would be necessary.
8. EARNINGS PER SHARE (EPS).
The computation of per share amounts for the three and six months ended
June 30, 2000 is based on the average number of common shares outstanding for
the period. Options and warrants to purchase 1,759,903 and 3,199,154 shares of
common stock outstanding during the three months ended June 30, 2000 and three
months ended June 30, 1999, respectively, were not considered in the computation
of diluted EPS because their inclusion would have been antidilutive. Options and
warrants to purchase 1,756,903 and 3,199,154 shares of common stock outstanding
during the six months ended June 30, 2000 and six months ended June 30, 1999,
respectively, were not considered in the computation of diluted EPS because
their inclusion would have been antidilutive. Preferred stock convertible into
2,000,000 common shares at June 30, 1999, was also not considered in the
computation of diluted EPS for six-month period then ended because their
inclusion would have been antidilutive.
The following is a reconciliation of shares used in computing basic and
diluted earnings per share amounts.
Three Months Three Months Six Months
ended 6/30/99 ended 6/30/00 ended 6/30/00
------------- ------------- -------------
Weighted average number of shares - basic 6,490,422 9,649,658 9,513,836
Effects of Dilutive Securities
Options 3,479 247,466 319,918
Warrants -- 122,766 142,182
Preferred Stock 2,000,000 306,000 304,368
--------- ---------- ----------
Weighted average number of shares - diluted 8,493,901 10,325,890 10,280,304
========= ========== ==========
9. DISCONTINUED OPERATIONS.
In March 2000, the Board of Directors approved a plan of disposal for its
wholly-owned subsidiary, Perceptive Scientific Instruments, LLC ("PSI"), the
Company's genetic analysis business segment. The Company completed the sale of
substantially all of PSI's U.S. operations to Applied Imaging Corporation
(Nasdaq: AICX) on July 6, 2000. The purchase price consisted of 385,371 shares
Applied Imaging common stock, the assumption of
12
14
certain liabilities and potential cash payments based on future performance of
Applied Imaging's business. The Company was unable to sell PSI's international
operations and placed Perceptive Scientific International Limited (a
wholly-owned subsidiary of PSI) into a voluntary liquidation under United
Kingdom law on June 6, 2000.
The results of discontinued operations for the six months ended June 30,
2000 consisted of the following:
Operating loses, net of tax through March 31, 2000 $ (286,385)
Loss on disposal:
Operating losses, net of tax from March 31, 2000
to June 30, 2000 $ (340,827)
Gain on disposal of net assets 141,668
----------
(199,159)
----------
Total loss from discontinued operations $ (485,544)
==========
Revenues from discontinued operations for the three and six months ended
June 30, 2000 were $442,665 and $1,227,400, respectively.
The operating results of the discontinued operations for the three and six
months ended June 30, 1999 are summarized as follows:
Three Months Six Months
----------- -----------
Revenues $ 1,248,070 $ 2,381,518
Loss from discontinued operations (235,902) (625,246)
The cash flow data of the discontinued operations for the six months ended
June 30, 1999 were not separately detailed in the statement of cash flows, but
are summarized below:
Cash used by operations $(191,669)
Cash used by investing activities (56,739)
Effect of foreign currency fluctuations on
cash equivalents 15,106
---------
Cash used by discontinued operations $(233,302)
=========
10. SEGMENT AND GEOGRAPHIC INFORMATION.
The Company's continuing operations are organized on the basis of products
and related services and under FAS 131 operates in two segments: (1) urinalysis
and (2) small laboratory devices.
The urinalysis segment designs, develops, manufactures and markets IVD
imaging systems based on patented and proprietary AIM technology for automating
microscopic procedures for urinalysis. In December 1997, this segment also began
distributing the UF-100 urine cell analyzer in the United States under an
existing agreement with its manufacturer. The segment also provides ongoing
sales of supplies and service necessary for the operation of installed
urinalysis workstations. In the United States, these products are sold through a
direct sales force. Internationally, these products are sold through
distributors.
13
15
The small laboratory devices segment designs, develops, manufactures and
markets a variety of benchtop centrifuges, small instruments and supplies. These
products are used primarily for manual specimen preparation and dedicated
applications in coagulation, cytology, hematology and urinalysis. These products
are sold worldwide through distributors.
The accounting policies of the segments are the same as those described in
the "Summary of Significant Accounting Policies" included in the Company's
report on Form 10-K for the year ended December 31, 1999. The Company evaluates
the performance of its segments and allocates resources to them based on
earnings before income taxes, excluding corporate charges ("Segment Profit").
The tables below present information about reported segments for the three
and six month periods ended June 30, 2000 and 1999:
Three Months Ended June 30, 2000:
---------------------------------
Small Unallocated
Laboratory Corporate
Urinalysis Devices Expenses Total
---------- ------- -------- -----
Revenues $ 5,690,300 $1,786,181 -- $ 7,476,481
Interest income $ 50,061 -- -- $ 50,061
Interest expense $ 125 -- $ 242,751 $ 242,876
Depreciation and amortization $ 193,089 $ 29,884 $ 62,279 $ 285,252
Segment profit (loss) $ 1,276,794 $ 519,712 $ (730,097) $ 1,066,409
Segment assets $13,099,056 $2,105,380 $ 10,661,313 $25,865,749
Investment in long-lived assets $ 69,643 $ 17,237 -- $ 86,880
Three Months Ended June 30, 1999:
---------------------------------
Small Unallocated
Laboratory Corporate
Urinalysis Devices Expenses Total
---------- ------- -------- -----
Revenues $ 4,994,033 $1,123,815 -- $ 6,117,848
Interest income $ 8,965 $ 674 -- $ 9,639
Interest expense $ 1,326 -- $ 260,406 $ 261,732
Depreciation and amortization $ 260,933 $ 39,311 $ 12,577 $ 312,821
Segment profit (loss) $ 1,214,150 $ 223,724 $(1,216,388)(1) $ 221,486
Segment assets $11,312,645 $1,903,788 $ 9,181,543 $22,397,976
Investment in long-lived assets $ 94,887 $ 16,255 -- $ 111,142
(1) Includes unusual legal expenses of $426,542.
14
16
Six Months Ended June 30, 2000:
-------------------------------
Small Unallocated
Laboratory Corporate
Urinalysis Devices Expenses Total
---------- ------- -------- -----
Revenues $11,100,609 $3,129,010 -- $14,229,619
Interest income $ 83,318 -- -- $ 83,318
Interest expense $ 1,080 -- $ 483,547 $ 484,627
Depreciation and amortization $ 356,379 $ 58,627 $ 75,005 $ 490,011
Segment profit (loss) $ 2,775,492 $ 841,184 $(1,535,022) $ 2,081,654
Investment in long-lived assets $ 158,342 $ 25,137 -- $ 183,479
Six Months Ended June 30, 1999:
-------------------------------
Small Unallocated
Laboratory Corporate
Urinalysis Devices Expenses Total
---------- ---------- ----------- ------------
Revenues $9,348,553 $2,258,085 -- $ 11,606,638
Interest income $ 15,430 $ 1,219 -- $ 16,649
Interest expense $ 2,723 -- $ 541,353 $ 544,076
Depreciation and amortization $ 524,267 $ 80,859 $ 22,340 $ 627,466
Segment profit (loss) $2,228,063 $ 476,913 $(3,587,320)(1) $ (882,344)
Investment in long-lived assets $ 178,566 $ 20,790 -- $ 199,356
(1) Includes litigation settlement and unusual legal expenses of $2,043,273.
Long-lived assets for continuing operations were all located in the United
States and totaled $2,646,393 at December 31, 1999 and $3,473,688 at June 30,
2000.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
INTRODUCTION
We sold Perceptive Scientific Instruments, our genetic analysis business,
on July 6, 2000 as part of a plan to refocus on our core business. We have
treated this business as a discontinued operation for accounting purposes, and
we have removed it from most of the discussion and financial information in this
Quarterly Report. For a further discussion of the sale of this business, please
see the section entitled "Discontinued Business Operations" on page 20 of this
Quarterly Report.
OVERVIEW
We generate revenues primarily from sales of The Yellow IRIS urinalysis
workstation, an in vitro diagnostic, or IVD, imaging system based on our
patented and proprietary AIM technology, and the related supplies and service
required to operate this workstation. We also earn revenues from sales of
ancillary lines of small laboratory
15
17
instruments and supplies. Until 1996, we marketed just two models of The Yellow
IRIS urinalysis workstation. These models differ mainly in speed and price. In
1996, we introduced a third model of The Yellow IRIS, the Model 900UDx urine
pathology system. This model is a higher capacity automated urinalysis
workstation designed especially for the high-volume testing requirements of
large hospitals and reference laboratories. In December 1997, we began
distributing the IRIS/Sysmex UF-100 urine cell analyzer in the United States
under an exclusive agreement with its manufacturer, Sysmex Corporation. We did
not have significant sales of the UF-100 in 1998, 1999 or 2000. In September
1998, Sysmex started procedures to end the exclusive nature of our distribution
rights, claiming inadequate sales performance. We denied these allegations.
Sysmex has announced that its U.S. subsidiary will distribute the UF-100 in
North America. We may take legal action. We cannot predict the impact on the
Company of this announcement or any legal action we may take.
Because of the nature of our business, we make significant investments in
research and development for new products and enhancements to existing products.
In the past, we have partially funded our research and development programs
through grants from the National Institutes of Health, joint development
programs with strategic partners and Company-sponsored research and development
entities. We anticipate that future expenditures on research and development
will increase significantly and will be funded primarily out of the Company's
earnings.
The following table summarizes total product technology expenditures for
the periods indicated:
Three Months Ended June 30 Six Months Ended June 30
-------------------------- ------------------------
1999 2000 1999 2000
---------- ---------- ---------- ----------
Research and development expense, net $ 280,000 $ 597,000 $ 584,000 $1,021,000
Capitalized software development costs 73,000 17,000 142,000 32,000
Reimbursed costs for research and
development grants and contracts 137,000 262,000 214,000 451,000
---------- ---------- ---------- ----------
Total product technology expenditures $ 490,000 $ 876,000 $ 940,000 $1,504,000
========== ========== ========== ==========
In 1995, we entered into a joint development project with Poly U/A Systems,
Inc. for development of several new products to enhance automated urinalysis.
Subsequently, certain disputes arose with the Poly U/A shareholders. In 1999, we
made a tender offer to acquire all of the outstanding shares of Poly U/A stock
for a package of IRIS securities with an estimated value of up to $1.5 million.
Approximately 77% of the outstanding shares of Poly U/A were tendered in this
transaction. We subsequently purchased most the remaining shares of Poly U/A
stock in several negotiated transactions. Poly U/A is now a 99% owned subsidiary
of IRIS. We have recorded the cost of purchasing Poly U/A stock as a litigation
settlement expense.
RESULTS OF OPERATIONS
COMPARISON OF THREE MONTHS ENDED JUNE 30, 2000 TO THREE MONTHS ENDED
JUNE 30, 1999
Net revenues for the quarter ended June 30, 2000 totaled $7.5 million, an
increase of $1.4 million, or 22%, over the same period last year. Sales of IVD
imaging systems increased to $2.0 million from $1.7 million, an increase of
$289,000, or 17% from the comparable period last year. Sales of IVD system
supplies and services increased to $3.6 million from $3.2 million, an increase
of $395,000 or 12% over the comparable period last year, primarily due to the
larger installed base of The Yellow IRIS IVD imaging systems. Sales of small
instruments and supplies increased to $1.8 million from $1.1 million, an
increase of $662,000, or 59% over the comparable to the same period last year.
Royalties and licensing revenues increased to $49,000 in the current quarter
from $37,000 in the same period last year.
Revenues from the urinalysis segment totaled $5.7 million in the current
quarter as compared to $5.0 million in the same quarter of last year, an
increase of $700,000. This growth is due to increased sales of The Yellow IRIS
family of workstations, increased sales of related system supplies and services
to the growing installed base. Revenues from small laboratory devices increased
to $1.8 million in the current quarter, as compared to $1.1 million in the same
quarter last year, an increase of $662,000. This growth is primarily due to
increased sale of instruments.
16
18
Cost of goods for IVD systems decreased as a percentage of sales of IVD
imaging systems to 66% for the quarter ended June 30, 2000 from 67% for the
comparable period last year. Cost of goods for IVD imaging system supplies and
services as a percentage of sales of such products was 38% for the current
period compared to 43% in the same period last year. Cost of goods for small
instruments and supplies as a percentage of sales of small instruments and
supplies totaled 52% for the current quarter compared to 55% for the comparable
period last year due to increased sales volume. The aggregate gross margin
totaled 51% for the current quarter as compared to 48% in the same quarter last
year.
Cost of goods sold as a percentage of revenues from the urinalysis segment
totaled 48% this quarter as compared to 51% in the same quarter of last year.
Cost of goods for small laboratory devices as a percentage of revenues totaled
52% in the current period, as compared to 55% in the same quarter of last year.
This decrease is due to increased sales volume.
Marketing and selling expenses totaled $1.0 million for the quarter ended
June 30, 2000, compared to $848,000 in the same period last year, an increase of
$163,000 or 19%. Marketing and selling expenses as a percentage of net revenues
was 14% in the current quarter, which was the same as last year.
General and administrative expenses increased to $949,000 for the current
quarter ended June 30, 2000 as compared to $846,000 for the comparable period
last year, an increase of $102,000 or 12%. This increase is primarily due to
accrued management bonuses based on second quarter profitability. General and
administrative expenses for the quarter as a percentage of net revenues was 13%
in the current year as compared to 14% in the prior year.
Net research and development expenses increased to $597,000 for the quarter
ended June 30, 2000 from $280,000, an increase of $317,000 or 113% from the
comparable period last year. Net research and development expenses as a
percentage of revenues increased to 8% from 5% in the year-ago period. Total
product technology expenditures, including capitalized software development
costs and reimbursed costs under research and development grants and contracts,
increased to $876,000 from $490,000, an increase of $386,000 or 79% as compared
to the comparable period last year. The increase in total product technology
expenditures is due to increased spending under a major project focused on The
Yellow IRIS workstation. We began this project in 1999 to improve The Yellow
IRIS urinalysis workstation product line. As a result, we expect significant
increases in our net research and development expenses above 1999 levels. We
have completed feasibility studies on the proposed improvements. We believe that
this project is important to maintaining our competitive position in the
urinalysis market and that our failure to successfully complete this project on
schedule could have a material and adverse effect on future system sales.
Amortization of intangible assets reflects the amortization of acquired
intangible assets and patents. Amortization of intangible assets for the quarter
ended June 30, 2000 decreased to $34,000 from $70,000, a decrease of $36,000 or
52% from the comparable period last year. The decline is the result of the write
off in the third quarter of 1999 of The White IRIS and deferred warrant costs.
The results of operations for the quarter ended June 30, 2000 did not
include any unusual expenses as compared to $427,000 in the prior year's
quarter. The prior year's expenses related primarily to the settlement with Poly
UA and legal expenses for an arbitration with the former owner of Perceptive
Scientific Instruments.
The net result was operating income of $1.2 million for the quarter ended
June 30, 2000 as compared to $473,000 for the same quarter last year. Excluding
the unusual expenses, operating income totaled $1.2 million for the first
quarter of 2000 as compared $899,000 for the same quarter last year.
Interest expense decreased to $243,000 for the quarter ended June 30, 2000
from $262,000 for the comparable period last year due to reduced indebtedness,
partially offset by increased interest rates on our credit facility.
For the quarter ended June 30, 2000, urinalysis segment profits increased
to $1.3 million as compared to $1.2 million in the same period last year, an
increase of $63,000, or 5%. Segment profits from the small laboratory devices
segment totaled $520,000 in the current quarter as compared to $224,000 in the
same period last year. The improvement was the result of increased product sales
and gross margins. Unallocated corporate
17
19
expenses totaled $730,000 in the current period as compared to $1.2 million in
the comparable period last year, a decrease of $486,000. This decrease is due
primarily to the fact that 1999 numbers included unusual legal expenses of
$427,000.
The income tax provision for the quarter ended June 30, 2000 was $392,000,
as compared to $105,000 for the comparable period in 1999. The difference
reflects the Company's improved profitability in the second quarter of 2000 as
compared to the comparable prior period. The difference between the effective
rate and the federal statutory rate for the three months ended June 30, 1999
relates primarily to an increase in the deferred tax valuation allowance
relating to net operating loss carryforwards generated by the litigation
settlement with Poly UA.
We had income from continuing operations of $674,000 or $0.07 per diluted
share for the quarter ended June 30, 2000 as compared to $116,000 or $0.01 per
diluted share for the quarter ended June 30, 1999.
COMPARISON OF SIX MONTHS ENDED JUNE 30, 2000 TO SIX MONTHS ENDED JUNE
30, 1999
Net revenues for the six months ended June 30, 2000 totaled $14.2 million,
an increase of $2.6 million, or 23%, over the same period last year. Sales of
IVD imaging systems increased to $3.5 million from $2.8 million, an increase of
$763,000, or 28% from the comparable period last year. Sales of IVD system
supplies and services increased to $7.2 million from $6.5 million, an increase
of $665,000 or 10% over the comparable period last year, primarily due to the
larger installed base of The Yellow IRIS IVD imaging systems. Sales of small
instruments and supplies increased to $3.1 million from $2.3 million, an
increase of $871,000, or 39% over the comparable period last year. Royalties and
licensing revenues increased to $426,000 in the current six-month period from
$102,000 in the same period last year. The increase was due to the receipt of a
$300,000 license fee in connection with expanded licensing of several existing
patents.
Revenues from the urinalysis segment totaled $11.1 million in the current
six-month period as compared to $9.3 million in the same period of last year, an
increase of $1.8 million. This growth is due to increased sales of The Yellow
IRIS family of workstations, increased sales of related system supplies and
services to the growing installed base and a license fee in connection with
expanded licensing of several existing patents. Revenues from small laboratory
devices increased to $3.1 million in the current six-month period, as compared
to $2.3 million in the same period last year, an increase of $871,000. This
growth is primarily due to increased sale of instruments.
Cost of goods for IVD systems as a percentage of sales of IVD imaging
systems was 66% for the six months ended June 30, 2000 which was comparable to
last year. Cost of goods for IVD imaging system supplies and services as a
percentage of sales of such products was 41% for the current period compared to
43% in the same period last year. Cost of goods for small instruments and
supplies as a percentage of sales of small instruments and supplies totaled 52%
for the current period compared to 54% for the comparable period last year due
to increased sales volume. The aggregate gross margin totaled 52% for the
current period as compared to 49% in the same period last year.
Cost of goods sold as a percentage of revenues from the urinalysis segment
totaled 47% for the six months ended June 30, 2000 as compared to 50% in the
same period of last year. This decrease is due to the impact on revenues of the
license fee. Cost of goods for small laboratory devices as a percentage of
revenues totaled 52% in the current period, as compared to 54% in the same
period of last year. This decrease is due to increased sales volume.
Marketing and selling expenses totaled $1.8 million for the six months
ended June 30, 2000, compared to $1.7 million in the same period last year, an
increase of $116,000 or 7%. Marketing and selling expenses as a percentage of
net revenues was 13% in the current period as compared to 15% last year.
General and administrative expenses increased to $2.0 million for the six
months ended June 30, 2000 as compared to $1.6 million for the comparable period
last year, an increase of $365,000 or 23%. This increase is primarily due to
accrued management bonuses based on improved profitability. General and
administrative expenses for the period as a percentage of net revenues was 14%
in the current year which was comparable to the prior year.
18
20
Net research and development expenses increased to $1.0 million for the six
months ended June 30, 2000 from $584,000, an increase of $436,000 or 75% from
the comparable period last year. Net research and development expenses as a
percentage of revenues increased to 7% from 5% in the prior year. Total product
technology expenditures, including capitalized software development costs and
reimbursed costs under research and development grants and contracts, increased
to $1.5 million from $940,000, an increase of $564,000 or 60% as compared to the
comparable period last year. The increase in total product technology
expenditures is due to increased spending under a major project focused on The
Yellow IRIS workstation. We began this project in 1999 to improve The Yellow
IRIS urinalysis workstation product line. As a result, we expect significant
increases in our net research and development expenses above 1999 levels. We
have completed feasibility studies on the proposed improvements. We believe that
this project is important to maintaining our competitive position in the
urinalysis market and that our failure to successfully complete this project on
schedule could have a material and adverse effect on future system sales.
Amortization of intangible assets reflects the amortization of acquired
intangible assets and patents. Amortization of intangible assets for the six
months ended June 30, 2000 decreased to $71,000 from $140,000, a decrease of
$70,000 or 50% from the comparable period last year. The decline is the result
of the write off in the third quarter of 1999 of The White IRIS and deferred
warrant costs.
The results of operations for the six months ended June 30, 2000 did not
include any unusual expenses as compared to $2.0 million in the prior year's
period. The prior year's expenses related primarily to the settlement with Poly
UA and legal expenses for an arbitration with the former owner of Perceptive
Scientific Instruments.
The net result was operating income of $2.5 million for the six months
ended June 30, 2000 as compared to an operating loss of $358,000 for the same
period last year. Excluding the unusual expenses, operating income totaled $2.5
million for the first six months of 2000 as compared $1.7 million for the same
period last year.
Interest expense decreased to $485,000 for the six months ended June 30,
2000 from $544,000 for the comparable period last year due to reduced
indebtedness, partially offset by increased interest rates on our credit
facility.
For the six months ended June 30, 2000, urinalysis segment profits
increased to $2.8 million as compared to $2.2 million in the same period last
year, an increase of $547,000, or 25%. This increase is largely due to higher
revenue and improved gross margins partially offset by higher operating
expenses. Segment profits from the small laboratory devices segment totaled
$841,000 in the current six-month period as compared to $477,000 in the same
period last year. The improvement was the result of increased product sales and
gross margins. Unallocated corporate expenses totaled $1.5 million in the
current period as compared to $3.6 million in the comparable period last year, a
decrease of $2.1 million. This decrease is due primarily to the fact that 1999
numbers included a litigation settlement and unusual legal expenses of $2.0
million.
The income tax provision for the six months ended June 30, 2000 was
$770,000, as compared to an income tax benefit $69,000 for the comparable period
in 1999. The difference reflects the Company's profitability in the first six
months of 2000 as compared to its net loss for the comparable prior period. The
difference between the effective rate and the federal statutory rate for the six
months ended June 30, 1999 relates primarily to an increase in the deferred tax
valuation allowance relating to net operating loss carryforwards generated by
the litigation settlement with Poly UA.
We had income from continuing operations of $1,311,000 or $0.13 per diluted
share for the six months ended June 30, 2000 as compared to a loss from
continuing operations of $814,000 or $0.12 per diluted share for the six months
ended June 30, 1999.
LIQUIDITY AND CAPITAL RESOURCES
Cash and cash equivalents increased to $3.0 million at June 30, 2000 from
$2.0 million at December 31, 1999. The increase is due to the cash provided by
operations in excess of amounts used by investing and financing activities. Cash
provided by operations for the six months ended June 30, 2000 increased to $2.1
million from $1.5 million for the comparable period last year. This increase is
primarily due to improved operations.
19
21
Cash used by investing activities totaled $320,000 for the six months ended
June 30, 2000, as compared to $171,000 in the same period last year. The
increase is primarily due to the increase in net expenditures for property and
equipment.
The credit facility with Foothill Capital Corporation, a Wells Fargo
company, consists of a $3.6 million term loan and a $4.0 million revolving line
of credit. Borrowings under the line of credit are limited to a percentage of
eligible accounts receivable and are subject to a combined limit of $7.0 million
for the total credit facility. The term loan bears interest at the lender's
prime rate (9.5% on June 30, 2000) plus 3.0%, and is payable in 36 equal monthly
installments. The revolving line of credit bears interest at the lender's prime
rate plus 1.0%. The credit facility is subject to minimum interest charges,
prepayment penalties and customary fees, is collateralized by a first priority
lien on all the assets of the Company and matures in 2001. It also contains
financial covenants based primarily on tangible net worth and cash flow and
imposes restrictions on acquisitions, capital expenditures and cash dividends.
We were in compliance with all of the financial covenants at June 30, 2000.
We began a major project in 1999 to improve The Yellow IRIS urinalysis
workstation product line. As a result, we are incurring increased expenditures
for our research and development. We plan to fund this project with cash from
operations.
Net cash used by financing activities totaled $829,000 and consisted
primarily of principal payments made on the term loan described above and net
repayments of amounts borrowed under the revolving line of credit. As of June
30, 2000, $1.1 million was outstanding under the term loan and $381,000 was
outstanding under the revolving line of credit; $2.2 million remained available
for future borrowings under the revolving credit line.
We reduced our outstanding borrowings by $900,000 in the first six months
of 2000 and we have scheduled principal payments totaling $1.1 million during
the next 12 months. We believe that our current cash on hand, together with cash
generated from operations and cash available under the credit facility, will be
sufficient to fund normal operations and pay principal and interest on
outstanding debt obligations for at least the next 12 months. On July 31, 2001,
our $7.0 million subordinated note becomes due and payable. We anticipate that
we will have to seek proceeds from a debt or equity financing in order to meet
this obligation.
We had 204,000 shares of Series B Callable Preferred Stock outstanding on
June 30, 2000. These shares have a liquidation preference of $3 per share (or an
aggregate liquidation preference of $612,000). The "callable" feature entitles
us to convert the preferred stock at any time into a number of shares of common
stock equal to the liquidation value divided by the market price of the common
stock at the time of conversion (subject to a minimum value of $2.00 per share
of common stock). The preferred stock will automatically convert under the same
formula on August 3, 2002 if we have not converted it sooner. Based on the
average closing price of $2.08 for the five consecutive trading days ending July
31, 2000, the call price would be $2.08, and we could convert the Series B
Callable Preferred Stock into 294,231 shares of common stock. The Series B
Callable Preferred Stock is non-voting, is not entitled to any preferred
dividends, and is not subject to any mandatory or optional redemption
provisions. We are not permitted to pay cash dividends on our common stock or to
repurchase any shares of our common stock without the written consent of the
holders of a majority of the Series B Callable Preferred Stock.
DISCONTINUED BUSINESS OPERATIONS
We acquired Perceptive Scientific Instruments in July 1996. Its principal
product line is the PowerGene family of genetic analyzers - IVD imaging systems
for karyotyping, DNA probe analysis and comparative genomic hybridization. We
sold the U.S. operations of Perceptive Scientific Instruments to Applied Imaging
Corporation (Nasdaq: AICX) on July 6, 2000. The purchase price consisted of
385,371 shares of Applied Imaging common stock, the assumption of certain
liabilities and potential cash payments based on future performance of Applied
Imaging's business. We retained the research group, including its federally
funded research grants. We were unable to sell the international operations and
placed Perceptive Scientific International Limited (a wholly-owned subsidiary of
Perceptive Scientific Instruments) into a voluntary liquidation under United
Kingdom law on June 6, 2000. We have classified Perceptive Scientific
Instruments as a discontinued operation for accounting purposes and have removed
it from most of the discussion and financial information in our 1999 Annual
Report and 2000 Quarterly Reports.
SHAREHOLDER RIGHTS PLAN
20
22
We have a shareholders rights plan. The rights are not presently
exercisable. They become exercisable only if a person or group acquires 20% or
more of our common stock, or announces a tender offer for 20% or more of our
common stock, without board approval. If the rights are triggered, all common
stockholders (except the hostile party) will be entitled to purchase shares of
common stock (or the economic equivalent in preferred stock) at a price based on
a substantial discount from the market price of the common stock. The Board of
Directors may terminate the plan at any time or redeem the rights prior to their
becoming exercisable. The rights expire on December 22, 2009.
NET OPERATING LOSS CARRYFORWARDS
At December 31, 1999, we had federal net operating loss carryforwards of
approximately $17.5 million. If substantially all of our outstanding options and
warrants are exercised, these transactions in combination with other prior stock
issuances during the past three years would constitute a "change of ownership"
under Section 382 of the Internal Revenue Code. Section 382 imposes an annual
limitation on the utilization of net operating loss carryforwards based on a
statutory rate of return (usually the applicable federal rate) and the value of
the corporation at the time of the change of ownership. Depending on the market
price of our common stock at the time a change of ownership occurs, the
resulting limitations imposed by Section 382 could trigger a substantial write
down in our deferred tax assets and a corresponding charge to earnings in the
relevant quarter.
INFLATION
The Company does not foresee any material impact on its operations from
inflation.
FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements
which reflect our current views about future events and financial results. We
have made these statements in reliance on the safe harbor created by the Private
Securities Litigation Reform Act of 1995. Forward-looking statements include our
views on future financial results, financing sources, product development,
capital requirements, market growth and the like, and are generally identified
by phrases such as "anticipates," "believes," "estimates," "expects," "intends,"
"plans" and similar words. Forward-looking statements are merely predictions and
therefore inherently subject to uncertainties and other factors which could
cause the actual results to differ materially from the forward-looking
statement. These uncertainties and other factors include, among other things,
- our ability to secure additional financing to repay the remaining
principal balance of our long-term debt and to fund our long-term
business strategy,
- unexpected technical and marketing difficulties inherent in major
product development efforts,
- the potential need for changes in our long-term strategy in response
to future developments,
- future advances in diagnostic testing methods and procedures, as well
as potential changes in government regulations and healthcare
policies, both of which could adversely affect the economics of the
diagnostic testing procedures automated by our products,
- rapid technological change in the microelectronics and software
industries, and
- increasing competition from imaging and non-imaging based in-vitro
diagnostic products.
We have attempted to identify additional significant uncertainties and
other factors affecting forward-looking statements in Exhibit 99 to our 1999
Annual Report on Form 10-K. Stockholders should understand that the
uncertainties and other factors identified in this Quarterly Report and in
Exhibit 99 to the Annual Report are not a comprehensive list of all the
uncertainties and other factors which may affect forward-looking statements. We
do not undertake any obligation to update or revise any forward-looking
statements or the list of uncertainties and other factors which could affect
those statements.
NEW ACCOUNTING PRONOUNCEMENTS
In December 1999, the Securities and Exchange Commission ("SEC") issued
Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial
Statements," which provides the SEC's views on applying generally accepted
accounting principles to selected revenue recognition issues. The SAB is
effective in the fourth quarter of this fiscal year. The Company is presently
evaluating the impact, if any, that this may have on the Company's revenue
recognition policies.
21
23
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There was no material change in the Company's exposure to market risk on
June 30, 2000 as compared to its market risk exposure on December 31, 1999. See
"Management's Discussion and Analysis of Financial Condition and Results of
Operations - Market Risk" in the Company's 1999 Annual Report on Form 10-K.
PART II
OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
The Company is not currently involved in any litigation.
ITEM 2. SALES OF UNREGISTERED SECURITIES.
We did not sell any unregistered securities in the quarter ended June 30,
2000 except as previously reported in our Form 10-Q for the quarter ended March
31, 2000.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
We held our annual meeting of stockholders on May 19, 2000. At the meeting,
our stockholder's voted on the following matters:
1. Election of Directors. The stockholders re-elected Mr. Steven
Besbeck and Dr. Richard G. Nadeau as Class 1 Directors. Mr. Besbeck received
6,975,763 votes for re-election, and 315,772 votes were withheld. Dr. Nadeau
received 6,978,465 votes for re-election, and 313,070 votes were withheld.
2. Amendment to the 1998 Stock Option Plan. The stockholders approved
an increase in the number of shares of common stock available for grant under
the 1998 Stock Option Plan from 600,000 shares to 1,200,000 shares, an increase
of 600,000 shares. The voting results were 3,713,083 votes for, 630,942 votes
against, 113,123 votes abstaining and 2,834,387 broker non-votes.
3. Ratification of Appointment of Independent Auditors. The
stockholders ratified the reappointment of the accounting firm of
PricewaterhouseCoopers LLP as independent auditors for the Company for 2000. The
voting results were 7,207,236 votes for, 64,810 votes against, 14,319 votes
abstaining and no broker non-votes.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
(a) Exhibits
Exhibit Reference
Number Description Document
- ------ ----------- --------
3.1(a) Certificate of Incorporation, as amended (1)
3.1(b) Certificate of Designations of Series A Convertible Preferred Stock (2)
3.1(c) Certificate of Designations of Series B Callable Preferred Stock (3)
3.1(d) Certificate of Designations, Preferences and Rights of Series C Preferred Stock (4)
3.2 Restated Bylaws (5)
4.1 Specimen of Common Stock Certificate (6)
4.2 Certificate of Designations of Series A Convertible Preferred Stock (2)
4.3 Certificate of Designations of Series B Callable Preferred Stock (3)
4.4 Certificate of Designations, Preferences and Rights of Series C Preferred Stock (4)
10.1 Asset Purchase Agreement dated as of July 6, 2000 among the Company, Perceptive --
Scientific Instruments, LLC and Applied Imaging Corporation
27 Financial Data Schedule 1999 --
Exhibits followed by a number in parenthesis are incorporated by reference
to the similarly numbered Company document cited below:
22
24
(1) Current Report on Form 8-K dated August 13, 1987 and Quarterly Report
on Form 10-Q for the quarter ended September 30, 1993.
(2) Current Report on Form 8-K dated January 15, 1997.
(3) Quarterly Report on Form 10-Q for the quarter ended June 30, 1999.
(4) Current Report on Form 8-K dated January 26, 2000.
(5) Quarterly Report on Form 10-Q for the quarter ended September 30, 1994.
(6) Registration Statement on Form S-3, as filed with the Securities and
Exchange Commission on March 27, 1996 (File No. 333-002001).
(b) Reports on Form 8-K
On May 23, 2000, the Company filed a Form 8-K announcing the signing of a
new letter of intent for the sale of the U.S. operations of Perceptive
Scientific Instruments, LLC, its wholly-owned subsidiary engaged in the genetic
analysis business.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized, in Chatsworth, California, on August 14,
2000.
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
By: /s/ Donald E. Horacek
---------------------------------------
Donald E. Horacek
Controller and Secretary
[Authorized Signatory and Principal
Accounting Officer]
23
25
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
EXHIBITS
TO
FORM 10-Q
FOR THE FISCAL QUARTER ENDED JUNE 30, 2000
COMMISSION FILE NO. 1-9767
INTERNATIONAL REMOTE IMAGING SYSTEMS, INC.
26
EXHIBIT INDEX
Exhibit Reference
Number Description Document
- ------ ----------- --------
3.1(a) Certificate of Incorporation, as amended (1)
3.1(b) Certificate of Designations of Series A Convertible Preferred Stock (2)
3.1(c) Certificate of Designations of Series B Callable Preferred Stock (3)
3.1(d) Certificate of Designations, Preferences and Rights of Series C Preferred Stock (4)
3.2 Restated Bylaws (5)
4.1 Specimen of Common Stock Certificate (6)
4.2 Certificate of Designations of Series A Convertible Preferred Stock (2)
4.3 Certificate of Designations of Series B Callable Preferred Stock (3)
4.4 Certificate of Designations, Preferences and Rights of Series C Preferred Stock (4)
10.1 Asset Purchase Agreement dated as of July 6, 2000 among the Company, Perceptive --
Scientific Instruments, LLC and Applied Imaging Corporation
27 Financial Data Schedule 1999 --
Exhibits followed by a number in parenthesis are incorporated by reference
to the similarly numbered Company document cited below:
(1) Current Report on Form 8-K dated August 13, 1987 and Quarterly Report
on Form 10-Q for the quarter ended September 30, 1993.
(2) Current Report on Form 8-K dated January 15, 1997.
(3) Quarterly Report on Form 10-Q for the quarter ended June 30, 1999.
(4) Current Report on Form 8-K dated January 26, 2000.
(5) Quarterly Report on Form 10-Q for the quarter ended September 30, 1994.
(6) Registration Statement on Form S-3, as filed with the Securities and
Exchange Commission on March 27, 1996 (File No. 333-002001).